SRG Clinical Trials: September 2025
ProCares
This study will enroll individuals 45 years of age or older who present with symptoms, signs, and/or have findings leading to a clinical suspicion (but not yet diagnosed) OR newly diagnosed cancer of the following types of cancer:
Biliary Tract, Colon, Esophagogastric Junction, Esophagus, Gallbladder, Head and Neck, Liver, Lung, Lymphatic System, Ovary, Pancreas, Rectum, Stomach
One time blood collection
No prior cancer history
Newly diagnosed cancer must be enrolled into the study within 45 days of diagnosis
Sanofi Crohn’s
Moderate to severe active Crohn’s
Unique, first in class, Nanobody therapeutic protein directed at TNF and OX40L (which plays a role in T-helper cell differentiation and maintenance)
SC injections Q2weeks
Biologic naïve and failed standard treatment OR failed at least 1 biologic/advanced therapy therapy class but not more than 3
No fistulizing disease, ostomy or ileoanal pouch or missing more than 2 entire segments of colon
No opiate use or cannabis use (even if for medical reasons)
Total study length: 52 weeks with additional Open Label Period of 104 weeks
Sanofi UC
Moderate to severe, active UC with rectal bleeding
Unique, first in class, Nanobody therapeutic protein directed at TNF and OX40L (which plays a role in T-helper cell differentiation and maintenance)
SC injections Q2weeks
Biologic naïve and failed standard treatment OR failed at least 1 biologic/advanced therapy class
No ileal pouch or ostomy
No diagnosis of inflammatory conditions other than UC (including but not limited to systemic lupus erythematosus, systemic sclerosis, myositis, rheumatoid arthritis, primary biliary cirrhosis, multiple sclerosis, Behcet’s disease, sarcoidosis, etc)
Total study length: 52 weeks with additional Open Label Period of 104 weeks
T-Scan- UC
Ulcerative colitis- currently symptomatic
Blood only- one time visit
Biologic meds are allowed
NO- drugs that are known to be T cell toxic. The following treatments are not allowed and include:
Glucocorticoids including prednisone, methylprednisolone (Solumedrol), budesonide (Entocort), hydrocortisone (Solu-cortef), dexamethasone (Decadron), betamethasone (Betaject)
Sulfasalazine (Azulfidine)
Aminosalicylates including mesalamine/ mesalazine (Asacol, Pentasa).
Thiopurines including azathioprine (Imuran) and 6-mercaptopurine (Purixan)
Systemic JAK inhibitors including tofacitinib (Xeljanz), abrocitinib (Cibinqo), baricitinib (Olumiant), upadacitinib (Rinvoq)
Methotrexate
T-Scan- Crohn’s
Crohn’s with upcoming endoscopy procedure scheduled
Biologic meds are allowed
NO- drugs that are known to be T cell toxic. The following treatments are not allowed and include:
Glucocorticoids including prednisone, methylprednisolone (Solumedrol), budesonide (Entocort), hydrocortisone (Solu-cortef), dexamethasone (Decadron), betamethasone (Betaject)
Sulfasalazine (Azulfidine)
Aminosalicylates including mesalamine/ mesalazine (Asacol, Pentasa).
Thiopurines including azathioprine (Imuran) and 6-mercaptopurine (Purixan)
Systemic JAK inhibitors including tofacitinib (Xeljanz), abrocitinib (Cibinqo), baricitinib (Olumiant), upadacitinib (Rinvoq)
Methotrexate
CRC or Advanced Adenoma - Exact Sciences
Age 18 or older
Newly diagnosed CRC- not yet treated
Advanced Adenoma (>1cm remaining and biopsy proven) requiring follow up intervention
C-Diff- Vedanta
For patients with C-Diff who have had at least one prior occurrence of C-Diff within the last 6 months
VE303 is an oral, live biotherapeutic (taken in capsule form x 14 days) that will be administered following completion of a course of standard-of-care (SoC) antibiotics
Crohn’s- Abivax
Moderate to severely active Crohn’s disease
ABX464 is an oral, novel anti-inflammatory drug
Documented inadequate response (defined as lack of response or loss of response or intolerance) to at least one of the following treatments: corticosteroids (CS), immunosuppressants (IS), biologic or biosimilar therapies, or JAK
Subjects may receive study drug for up to 100 weeks
Idiopathic Gastroparesis CIN-102-124
(Deudomperidone) in Adult Subjects with Idiopathic Gastroparesis
Daily nausea
At least 1 episode of vomiting in a 2-week period
NO diabetic patients permitted
EOE- NSI-8226-201- Uniquity One
Diagnosis of EOE by endoscopic biopsy prior to screening, as demonstrated by intraepithelial eosinophilic infiltration (peak cell count ≥ 15 eosinophils/hpf from at least 1 esophageal region)
Participant reported weekly dysphagia in the last 4 weeks
Participants with previously documented standard of care treatment, which could include proton pump inhibitors (PPIs), swallowed topical corticosteroids (STCs), and/or diet, must agree not to change background medication
The study drug, Solrikitug, will be administered SC Q4 weeks
EOE-Dupixent Registry
A U.S. Registry of EOE patients treated with Dupixent as standard of care
Any patient being prescribed Dupixent for EOE should be invited to participate in the registry.
Patients should be enrolling into the study on the day of or PRIOR to first dose of Dupixent
NO treatment with Dupixent within the 6 months prior to screening
Total study length: 36 months (3 years) with 9 visits- all remote